GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Total Equity

NAMS (NewAmsterdam Pharma Co NV) Total Equity : $757.50 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Total Equity?

NewAmsterdam Pharma Co NV's total equity for the quarter that ended in Dec. 2024 was $757.50 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NewAmsterdam Pharma Co NV Total Equity Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Total Equity Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
-4.40 56.37 430.07 288.39 757.50

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 288.39 411.80 387.44 378.86 757.50

NewAmsterdam Pharma Co NV Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NewAmsterdam Pharma Co NV's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=864.62-107.12
=757.50

NewAmsterdam Pharma Co NV's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=864.62-107.12
=757.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV Total Equity Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » Total Equity
Comparable Companies
RXRX APGE MLTX MIRM VCEL BEAM EWTX FOLD XENE DNLI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.